CAJ | 학술논문

将86例胃癌晚期患者,利用SPSS 13.0软件生成随机数字分为观察组和对照组,每组各43例.观察组采用希罗达联合奥沙利铂(XELOX方案)治疗,对照组采用奥沙利铂+5-氟尿嘧啶+亚叶酸钙(FOLFOX.-4方案)治疗,采用实体瘤的疗效评价标准(RECIST)评价近期疗效,并比较两组患者不良反应发生率.观察组与对照组有效率分别为56％、51％,差异无统计学意义(P＞0.05).观察组骨髓抑制、恶心呕吐发生率低于对照组,差异具有统计学意义(P＜0.05),其余各项不良反应比较差异无统计学意义(P＞0.05).XELOX与FOLFOX-4方案对进展期胃癌近期疗效相近,XELOX方案不良反应轻,患者更易接受,依从性好.
장86례위암만기환자,이용SPSS 13.0연건생성수궤수자분위관찰조화대조조,매조각43례.관찰조채용희라체연합오사리박(XELOX방안)치료,대조조채용오사리박+5-불뇨밀정+아협산개(FOLFOX.-4방안)치료,채용실체류적료효평개표준(RECIST)평개근기료효,병비교량조환자불량반응발생솔.관찰조여대조조유효솔분별위56％、51％,차이무통계학의의(P＞0.05).관찰조골수억제、악심구토발생솔저우대조조,차이구유통계학의의(P＜0.05),기여각항불량반응비교차이무통계학의의(P＞0.05).XELOX여FOLFOX-4방안대진전기위암근기료효상근,XELOX방안불량반응경,환자경역접수,의종성호.
Objective A total of 86 cases with advanced gastric cancer were randomly divided into XELOX(capecitabine plus oxaliplatin) and FOLFOX4 (5-fluorouracil,leucovorin,and oxaliplatin)groups (n =43 each).The immediate efficacies were evaluated by the criteria of Response Evaluation Criteria In Solid Tumors (RECIST).Adverse reactions were compared between two groups.The overall effective rate were 56％ and 51％ in XELOX and FOLFOX4 groups.And there was no significant inter-group difference (P ＞ 0.05).The incidences of myelosuppression and nausea,vomiting in XELOX group were lower than those in FOLFOX4 group (P ＜ 0.05).And other adverse reactions had no inter-group statistical difference (P ＞ 0.05).Both chemotherapies were comparable in immediate efficacies for advanced gastric cancer.However,XELOX chemotherapy had a lower incidence of adverse reactions and it is more tolerable and compliant for patients.